HC Wainwright & Co. Maintains Buy on Alpine Immune Sciences, Raises Price Target to $50
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Joseph Pantginis maintains a Buy rating on Alpine Immune Sciences (ALPN) and raises the price target from $32 to $50.
March 19, 2024 | 10:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. maintains a Buy rating on Alpine Immune Sciences and increases the price target from $32 to $50.
The increase in price target from $32 to $50 by a reputable analyst firm like HC Wainwright & Co. suggests a strong confidence in Alpine Immune Sciences' future performance. This endorsement is likely to positively influence investor sentiment and could lead to a short-term increase in ALPN's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100